Plaintiff ARS Pharmaceuticals Operations Inc., a direct purchaser of components from Aptar for its own nasal spray product, claims it was forced to pay higher prices “than would prevail in a market unrestrained by Aptar’s exclusionary conduct,” it said in a Monday complaint filed in the US District Court for the Southern District of California.
ARS is a biopharmaceutical company that sources components of its “neffy” intranasal treatment spray for allergic reactions from Aptar. Aptar is ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.